There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| Ask | Qty | Orders |
|---|---|---|
Annual Revenue,rose 3.22%, in the last year to ₹1,680.98 Cr. Its sector's average revenue growth for the last fiscal year was 7.92%.Quarterly Revenue,rose 7% YoY to ₹432.12 Cr. Its sector's average revenue growth YoY for the quarter was 7.14%.Quarterly Net profit,rose 70.66% YoY to ₹9.96 Cr. Its sector's average net profit growth YoY for the quarter was 23.32%.
Camlin Fine Sciences Limited (CFS) is an India‑headquartered, listed speciality chemicals company incorporated on November 30, 1993. It engages in research, development, manufacturing and marketing of speciality chemicals, ingredients and additive blends across food, animal nutrition, pet food, pharmaceutical, petrochemical and industrial applications globally. The company’s portfolio spans Shelf‑Life Solutions (antioxidants and blends), Aroma Ingredients (including Vanillin and Ethyl Vanillin), Performance Chemicals (such as Hydroquinone, Catechol, MEHQ, TBC, Guaiacol, Veratrole) and Health & Wellness (algae‑based Omega‑3) . CFS manufactures aroma ingredients at its Dahej unit and is one of the largest manufacturers of Methyl Vanillin in the world . Blends manufacturing is spread across India, Mexico, Brazil, USA and Europe, and products are marketed globally through subsidiaries and distribution networks. In India, plants are at Tarapur (Thane) and Dahej (Bharuch), with R&D at Boisar and an application lab in Thane.
CFS serves customers in 56 countries and across 28 Indian States/UTs . As on March 31, 2025, the company had 21 subsidiaries (including step‑down subsidiaries) and 1 associate of a step‑down subsidiary; only the number is disclosed here. Recent milestones include mothballing the Italy diphenols facility in July 2023 and mitigating with a diphenols plant at Dahej, India.
Strategic footprint: CFS completed the acquisition of the Vitafor group (Belgium, China and related entities), which is included in consolidated operations for FY 2024‑25; an associate interest in Vial Sàrl (France) is also reflected.
Mexico restructuring: A reverse merger of CFS De Mexico Blends, S.A.P.I. DE C.V. into Dresen Quimica was executed with retrospective effect from February 28, 2025; approval was received on May 21, 2025 .
China update: The vanillin facility of CFS Wanglong Flavors (Ningbo) Co. Ltd., shut since February 19, 2021, is being closed with liquidation considered; results of these operations are presented as discontinued in FY 2024‑25.
New launches and R&D: The company developed a specialised grade of Hydroquinone, upgraded antioxidant offerings now commercialised, and introduced emulsifier‑based ingredients to enhance texture and processing outcomes for diverse food applications.
Financing and ratings: During FY 2024‑25, liquidity was supported by a rights issue and interim Non‑Convertible Debentures; India Ratings revised the company’s ratings to IND BBB/Negative (Term Loan), IND BBB/Negative/IND A3+ (Fund‑based) and IND A3+ (Non‑fund‑based) as at March 31, 2025.
CFS makes speciality chemicals, ingredients and blends used in food, animal nutrition, pet food, pharmaceuticals, petrochemicals and industrial applications . Its portfolio covers Shelf‑Life Solutions, Aroma Ingredients, Performance Chemicals and Health & Wellness .
In India, the company has plants at Tarapur (Thane) and Dahej (Bharuch), an R&D centre at Boisar and an application lab in Thane . Blends are manufactured across India, Mexico, Brazil, USA and Europe .
Exports contributed 64.84% of turnover in FY 2024‑25; the balance was from the domestic market . The company served customers in 56 countries during the year .
